Molecular Partners (MOLN) Competitors $3.72 +0.00 (+0.03%) Closing price 03:55 PM EasternExtended Trading$3.75 +0.03 (+0.75%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MOLN vs. TRML, SIGA, PVLA, IVA, MGTX, OPT, XNCR, ANAB, ARVN, and SVRAShould you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Tourmaline Bio (TRML), Siga Technologies (SIGA), Palvella Therapeutics (PVLA), Inventiva (IVA), MeiraGTx (MGTX), Opthea (OPT), Xencor (XNCR), AnaptysBio (ANAB), Arvinas (ARVN), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry. Molecular Partners vs. Its Competitors Tourmaline Bio Siga Technologies Palvella Therapeutics Inventiva MeiraGTx Opthea Xencor AnaptysBio Arvinas Savara Tourmaline Bio (NASDAQ:TRML) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations. Does the media prefer TRML or MOLN? In the previous week, Tourmaline Bio had 25 more articles in the media than Molecular Partners. MarketBeat recorded 27 mentions for Tourmaline Bio and 2 mentions for Molecular Partners. Tourmaline Bio's average media sentiment score of 0.66 beat Molecular Partners' score of -0.75 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 9 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Is TRML or MOLN more profitable? Tourmaline Bio's return on equity of -30.50% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -30.50% -29.63% Molecular Partners N/A -50.66%-45.13% Do analysts rate TRML or MOLN? Tourmaline Bio currently has a consensus target price of $45.61, suggesting a potential downside of 4.18%. Molecular Partners has a consensus target price of $8.00, suggesting a potential upside of 115.00%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts clearly believe Molecular Partners is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22Molecular Partners 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better earnings and valuation, TRML or MOLN? Molecular Partners has higher revenue and earnings than Tourmaline Bio. Tourmaline Bio is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$73.21M-$3.43-13.88Molecular Partners$5.65M26.59-$61.39M-$2.08-1.79 Do institutionals and insiders have more ownership in TRML or MOLN? 91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, TRML or MOLN? Tourmaline Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. SummaryTourmaline Bio beats Molecular Partners on 8 of the 15 factors compared between the two stocks. Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOLN vs. The Competition Export to ExcelMetricMolecular PartnersMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.25M$3.15B$5.76B$10.03BDividend YieldN/A2.28%5.28%4.52%P/E Ratio-1.7921.4575.4326.15Price / Sales26.59427.65515.98171.98Price / CashN/A45.5837.2059.76Price / Book0.939.5911.536.20Net Income-$61.39M-$53.33M$3.28B$270.56M7 Day Performance-0.13%0.61%0.42%2.70%1 Month Performance4.49%11.09%10.81%8.77%1 Year Performance-33.67%12.67%61.62%27.50% Molecular Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOLNMolecular Partners1.5822 of 5 stars$3.72+0.0%$8.00+115.0%-32.9%$150.25M$5.65M-1.79180TRMLTourmaline Bio0.9094 of 5 stars$23.57+0.7%$50.14+112.7%+171.0%$601.20MN/A-6.8744Trending NewsAnalyst ForecastSIGASiga Technologies1.5153 of 5 stars$8.63+2.9%N/A+9.9%$600.77M$138.72M7.6440PVLAPalvella Therapeutics1.9332 of 5 stars$52.71-2.7%$58.50+11.0%N/A$598.88M$42.81M-4.36N/AAnalyst ForecastIVAInventiva2.9319 of 5 stars$5.26-15.0%$13.67+159.8%+143.6%$592.15M$9.95M0.00100Gap DownHigh Trading VolumeMGTXMeiraGTx4.2931 of 5 stars$7.30flat$24.00+228.8%+90.3%$587.27M$33.28M-3.58300Positive NewsOPTOpthea0.2919 of 5 stars$3.41+7.2%$1.33-60.9%+8.6%$583.10M$120K0.008Positive NewsGap UpHigh Trading VolumeXNCRXencor3.8658 of 5 stars$8.55+5.2%$23.71+177.4%-58.2%$579.86M$110.49M-3.56280ANABAnaptysBio2.6117 of 5 stars$20.61+1.4%$46.13+123.8%-37.8%$569.18M$91.28M-4.60100Positive NewsARVNArvinas3.1245 of 5 stars$7.90+2.2%$19.76+150.2%-68.2%$567.52M$263.40M-7.82420Positive NewsSVRASavara3.2433 of 5 stars$3.31+0.9%$6.17+86.3%-10.3%$566.91MN/A-6.6220Trending NewsAnalyst Forecast Related Companies and Tools Related Companies Tourmaline Bio Competitors Siga Technologies Competitors Palvella Therapeutics Competitors Inventiva Competitors MeiraGTx Competitors Opthea Competitors Xencor Competitors AnaptysBio Competitors Arvinas Competitors Savara Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOLN) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersThis stock just surpassed PalantirThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOLN Stock Alerts